Greater Durability and Protection against Herpes Simplex Viral Disease following Immunization of Mice with Single-Cycle ΔgD-2 Compared to an Adjuvanted Glycoprotein D Protein Vaccine
Open Access
Abstract
Herpes simplex viruses (HSV) cause chronic infections with significant morbidity. Prior vaccines, designed to generate neutralizing antibodies (nAbs) targeting glycoprotein D (gD), failed to provide durable protection. We adopted a different strategy and evaluated a single-cycle virus deleted in gD (ΔgD-2). ΔgD-2elicits antibodies that primarily mediate antibody-dependent cell mediated cytolysis (ADCC) and provides complete protection against clinical isolates of HSV in multiple lethal mouse models. To assess durability, we vaccinated mice (2 doses administered intramuscularly) with ΔgD-2, adjuvanted recombinant gD-2 (rgD-2/Alum-MPL), or uninfected cells as a control, and quantified antibody responses over one year. Mice (n = 5/group) were lethally challenged at 2, 4, 6, 8, and 10-months post-boost. ΔgD-2-vaccinated mice elicited a durable ADCC-mediating response, which provided complete protection against challenge at all timepoints. In contrast, rgD-2/Alum-MPL elicited only nAbs, which declined significantly within 6 months, provided only partial protection at early timepoints, and no protection after 6 months. Serum sampling after viral challenge showed that infection elicited low levels of ADCC-mediating antibodies in rgD-2/Alum-MPL-vaccinated mice and boosted the nAb response, but only after 6 months. Conversely, infection significantly and consistently boosted both the ADCC and nAbs responses in ΔgD-2-vaccinated mice. Results recapitulate clinical trial outcomes with gD vaccines, highlight the importance of ADCC, and predict that ΔgD-2 will elicit durable responses in humans.Keywords
Funding Information
- National Institutes of Health (NIAID R01 AI 177673, R01 AI134367, P30 AI124414, T32AI007501)
- X-Vax Technology (NIAID R01 AI 177673, R01 AI134367, P30 AI124414, T32AI007501)
This publication has 33 references indexed in Scilit:
- Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural diseaseeLife, 2015
- Global Estimates of Prevalent and Incident Herpes Simplex Virus Type 2 Infections in 2012PLOS ONE, 2015
- Better Neutralization of Herpes Simplex Virus Type 1 (HSV-1) Than HSV-2 by Antibody From Recipients of GlaxoSmithKline HSV-2 Glycoprotein D2 Subunit VaccineThe Journal of Infectious Diseases, 2014
- HSV activates Akt to trigger calcium release and promote viral entry: novel candidate target for treatment and suppressionThe FASEB Journal, 2013
- Efficacy Results of a Trial of a Herpes Simplex VaccineNew England Journal of Medicine, 2012
- Evidence for Differences in Immunologic and Pathogenesis Properties of Herpes Simplex Virus 2 Strains From the United States and South AfricaThe Journal of Infectious Diseases, 2011
- Synergistic Copathogens — HIV-1 and HSV-2New England Journal of Medicine, 2007
- Impact of Immunization with Glycoprotein D2/AS04 on Herpes Simplex Virus Type 2 Shedding into the Genital Tract in Guinea Pigs That Become InfectedThe Journal of Infectious Diseases, 2005
- Herpes Simplex Virus (HSV) Type 2 Glycoprotein D Subunit Vaccines and Protection against Genital HSV‐1 or HSV‐2 Disease in Guinea PigsThe Journal of Infectious Diseases, 2003
- Glycoprotein-D–Adjuvant Vaccine to Prevent Genital HerpesNew England Journal of Medicine, 2002